Key facts
- Diogenx’s last known valuation is $21.2M (Dec 2024).
- It has raised $41.5M; the latest was Early Stage VC ($7.0M) in Dec 2024.
- Notable investors include European Innovation Council, Omnes Capital, Boehringer Ingelheim Venture Fund, Inserm Transfert, AdBio partners — 11 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Diogenx
- ·The full record, as it builds
Funding rounds
No funding rounds for Diogenx are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Diogenx
Developer of a biotechnology platform designed to regenerate insulin-producing beta cells for the treatment of diabetes. The company offers recombinant proteins that modulate the signalling pathway, enabling individuals with Type 1 glucose disregulation disorder to restore natural insulin production.
- Sector
- Healthcare
- HQ
- Marseille, France
- Founded
- 2020
- Employees
- 9
- Website
- diogenx.com/
- Ownership
- Privately Held (backing)
Diogenx doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Diogenx shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Diogenx in its N-PORT filings yet. We sweep new filings monthly.